ORAL PHARMACEUTICAL COMPOSITION SUITABLE FOR IMPROVING EFFECTIVENESS OF TREATMENT OF MOTOR DISORDERS Russian patent published in 2018 - IPC A61K9/22 A61K31/404 A61K31/506 A61K47/38 A61P25/16 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to the chemical-pharmaceutical industry and is a pharmaceutical composition for the treatment of a motor impairment, comprising a matrix component, comprising an active pharmaceutical ingredient which is an agonist of two or more 5-HT1B, 5-HT1D and 5-HT1F receptors, which is zolmitriptan or a pharmaceutically acceptable salt thereof, wherein said matrix component provides sustained release of said active pharmaceutical ingredient, and a component comprising an active pharmaceutical ingredient which is a 5-HT1A receptor agonist, which is buspirone or a pharmaceutically acceptable salt thereof, said component provides immediate release of said active pharmaceutical ingredient.

EFFECT: thus, by combining said two active ingredients, synergy is achieved as a result of both the combination itself and special release parameters of the pharmaceutical composition, which facilitates the administration and reduces the risk of side effects of each of the two active ingredients.

71 cl, 9 dwg, 5 tbl, 12 ex